Medication Administration Guidelines

Route of Administration

Tremor is more common with oral administration and nebulizer delivery, but less common with metered-dose inhalers (MDIs), especially when used with spacers, according to the American Academy of Family Physicians 1
The American Thoracic Society recommends considering ECG monitoring with the first dose in elderly patients with known ischemic heart disease, particularly when using albuterol, to monitor for potential cardiovascular effects 2
The use of albuterol may require monitoring for tachycardia, palpitations, or chest discomfort during initial treatment, especially in patients with pre-existing cardiac conditions, as stated by the American Thoracic Society 2

The American Heart Association suggests using the lowest effective dose of albuterol and considering a metered-dose inhaler with a spacer, as this delivery method results in less systemic absorption and fewer cardiovascular effects 3
High-dose, frequent administration of albuterol should be avoided in patients with significant cardiac disease, according to the American College of Cardiology 3
Patients with pathological murmurs should start with lower doses of albuterol (e.g., 2 puffs instead of 4) and use a spacer device with a metered-dose inhaler, as recommended by the American Heart Association 3

For elderly patients with heart disease, the European Respiratory Society recommends considering anticholinergic agents, like ipratropium, which may have fewer cardiovascular effects 2
The use of anticholinergic agents may be preferred over beta-agonists in elderly patients, as the response to beta-agonists may decline more rapidly with age compared to anticholinergics, as stated by the European Respiratory Society 2
The American Academy of Pediatrics states that albuterol is contraindicated in patients who have had heart transplants 4

Patients taking other medications that can lower potassium levels are at higher risk for complications from albuterol-induced hypokalemia, as noted by the National Asthma Education and Prevention Program 5
The European Society of Cardiology recommends monitoring heart rate and symptoms in patients with pathological murmurs using albuterol, and considering alternative bronchodilators if cardiac symptoms develop 2
Withholding needed bronchodilator therapy in acute respiratory distress can pose greater risks than the potential cardiovascular effects of albuterol in most cases, as stated by the American Thoracic Society 2
Albuterol can cause hypokalemia through beta2-adrenergic stimulation, resulting in decreased serum potassium levels, with studies showing mean decreases of 0.52-0.54 mmol/L in serum potassium levels due to albuterol use 6, 3
Patients with pre-existing cardiac disease are at higher risk for complications from albuterol-induced hypokalemia, and may experience adverse cardiovascular effects, including increased risk of myocardial infarction and arrhythmias 3
Routine potassium monitoring is not necessary for all patients receiving standard doses of albuterol via metered-dose inhalers, but may be considered for patients with cardiac risk factors or baseline electrolyte abnormalities, as recommended by the National Asthma Education and Prevention Program 5